Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T. Ohba A, et al. Among authors: sadachi r. Future Oncol. 2022 Jun;18(19):2351-2360. doi: 10.2217/fon-2022-0214. Epub 2022 May 5. Future Oncol. 2022. PMID: 35510484 Free article.
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J; Japan Clinical Oncology Group (JCOG). Morizane C, et al. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. doi: 10.1001/jamaoncol.2022.3395. JAMA Oncol. 2022. PMID: 35980649 Free PMC article. Clinical Trial.
Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study.
Koyama T, Shimizu T, Kojima Y, Sudo K, Okuma HS, Shimoi T, Ichikawa H, Kohsaka S, Sadachi R, Hirakawa A, Yoshida A, Ando RM, Ueno T, Yanagaki M, Matsui N, Nakamura K, Yamamoto N, Yonemori K. Koyama T, et al. Among authors: sadachi r. Cancer Discov. 2023 Aug 4;13(8):1814-1825. doi: 10.1158/2159-8290.CD-23-0419. Cancer Discov. 2023. PMID: 37369013 Clinical Trial.
Early Tumor Shrinkage and Depth of Response as Predictors of Survival for Advanced Biliary Tract Cancer: An Exploratory Analysis of JCOG1113.
Okano N, Morizane C, Okusaka T, Sadachi R, Kataoka T, Kobayashi S, Ikeda M, Ozaka M, Mizutani T, Sugimori K, Todaka A, Shimizu S, Mizuno N, Yamamoto T, Sano K, Tobimatsu K, Katanuma A, Gotoh K, Yamaguchi H, Ishii H, Ohba A, Furuse J, Ueno M; Hepatobiliary and Pancreatic Oncology Group of Japan Clinical Oncology Group (JCOG). Okano N, et al. Among authors: sadachi r. Oncologist. 2024 Jan 5;29(1):e97-e107. doi: 10.1093/oncolo/oyad220. Oncologist. 2024. PMID: 37531645 Free PMC article.
Association of renal function with the safety and efficacy of cisplatin plus S-1 therapy and docetaxel plus cisplatin plus S-1 therapy in patients with advanced gastric cancer: an exploratory analysis of JCOG1013.
Hironaka S, Sadachi R, Machida N, Iwasa S, Yamada Y, Sasako M, Yoshikawa T, Boku N, Terashima M. Hironaka S, et al. Among authors: sadachi r. Jpn J Clin Oncol. 2022 Jan 3;52(1):14-23. doi: 10.1093/jjco/hyab160. Jpn J Clin Oncol. 2022. PMID: 34668562
Antenatal Corticosteroids and Outcomes in Preterm Twins.
Ushida T, Kotani T, Sadachi R, Hirakawa A, Hayakawa M, Moriyama Y, Imai K, Nakano-Kobayashi T, Kikkawa F; Neonatal Research Network of Japan. Ushida T, et al. Among authors: sadachi r. Obstet Gynecol. 2020 Jun;135(6):1387-1397. doi: 10.1097/AOG.0000000000003881. Obstet Gynecol. 2020. PMID: 32459431
13 results